Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Financial Results:
Wockhardt Ltd reported Revenues for Q4FY24 of ₹700.00 Crores up from ₹678.00 Crore year on year, a rise of 3.24%.
Total Expenses for Q4FY24 of ₹934.00 Crores up from ₹807.00 Crores year on year, a rise of 15.74%.
Consolidated Net Profit of -₹177.00 Crores from -₹237.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹11.02, from -₹14.44 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.